Navigation Links
BioMS Medical updates University of Alberta equity position
Date:4/30/2010

Toronto Stock Exchange Symbol: MS

EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has sold 12,915,365 BioMS Medical shares.

Certain employees, officers and directors of BioMS Medical acquired 7,245,000 of the shares sold by the University of Alberta.

"We are very pleased that many of our senior management and Board members saw this as an opportunity to purchase these shares, recognizing the long-term prospects for the Company," said Kevin Giese, President and CEO of BioMS Medical. "We also thank the University of Alberta for their support over the past 10 years and continued involvement as a shareholder."

University of Alberta Vice President (Finance) Phyllis Clark added: "We have enjoyed a long and collaborative relationship with BioMS which we look forward to continuing in the future. The proceeds from the sale will be used to support the endowment fund and the teaching and research mission of the university."

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the investment, development and commercialization of pharmaceutical technologies. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces 2009 Year End Results
2. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. BioMS Medical provides corporate update
5. BioMS Medical Announces Third Quarter 2009 Results
6. BioMS Medical announces second quarter 2009 results
7. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
8. BioMS Medical to participate in panel session at Bio International Convention 2009
9. BioMS Medical Announces First quarter 2009 results
10. BioMS Medical to present at Alberta Economic Forum in Geneva
11. BioMS Medical to present at BioFinance 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... market news outlet had provided a research update on Aytu Bioscience and cited ... product. , According to Soulstring, prescription rates for Natesto® have more than doubled ...
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):